MB-101 (IL-13Rα2 CAR T)

About Fortress Biotech

Fortress Biotech operates as a biopharmaceutical accelerator, utilizing a flexible, therapeutic area-agnostic model to identify and advance high-potential assets. The company has achieved significant milestones, including the FDA approval of ZYCUBO® for Menkes disease and the sale of a Rare Pediatric Disease Priority Review Voucher for $205 million. By developing products both internally and through a network of majority-owned and minority partner companies, Fortress aims to create a diversified, long-term revenue stream from commercial products, royalties, and equity stakes.

Therapeutic Areas